Home › NDC Lookup › RxCUI directory › RxCUI 197433

Calcium acetate 667 MG Oral Tablet — RxCUI 197433

RxNorm drug concept · Semantic clinical drug
RxCUI 197433 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197433
Official nameCalcium acetate 667 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known ascalcium acetate 667 MG (calcium 169 MG) Oral Tablet; calcium 169 MG Oral Tablet, as calcium acetate
FDA products mapped2
Package NDCs mapped2
Reported Medicaid activity (SDUD)7,929 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Calcium Acetate: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It lowers the phosphorus in your blood if you have end stage renal disease. Failing kidneys can't clear phosphorus well, so it builds up. Calcium acetate helps by binding phosphate...
  • Take it by mouth with each meal. It needs to be in your stomach with your food to bind the phosphate. Your prescriber will adjust how many you take based on your blood tests, so fo...
  • The most common are high blood calcium, nausea and vomiting. Some people also report dizziness, swelling or weakness. Call your doctor if you have ongoing nausea, constipation, poo...
  • Avoid them unless your doctor says otherwise. Calcium supplements and calcium-based antacids add more calcium and raise the risk of high blood calcium. Check with me before taking...
📖 Read our full Calcium Acetate guide →

🕸️ Concept Web — How Calcium acetate 667 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Calcium acetate 667 MG Oral Tablet RxCUI 197433

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Calcium acetate 214342
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Calphron 215849
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Calcium acetate Oral Tablet 371195
    • Calcium acetate Oral Product 1164959
    • Calcium acetate Pill 1164960
    • Calcium acetate Oral Tablet [Calphron] 369168
    • Calphron Oral Product 1172265
    • Calphron Pill 1172266
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Calcium acetate 667 MG 329618
    • Calcium acetate 667 MG Oral Tablet [Calphron] 209010
    • Calcium acetate 667 MG [Calphron] 569650

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Calcium acetate 667 MG SCDC · 329618
  • Calcium acetate Oral Tablet SCDF · 371195
  • Calcium acetate Oral Product SCDG · 1164959
  • Calcium acetate Pill SCDG · 1164960

Brand-Name Concepts

  • Calcium acetate 667 MG Oral Tablet [Calphron] SBD · 209010
  • Calcium acetate 667 MG [Calphron] SBDC · 569650
  • Calcium acetate Oral Tablet [Calphron] SBDF · 369168
  • Calphron Oral Product SBDG · 1172265
  • Calphron Pill SBDG · 1172266
  • Calphron BN · 215849

📦 FDA Products & Package NDCs

2 products · 2 package NDCs
2 package NDCs map to RxCUI 197433 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
23155-0621-02 200 TABLET in 1 BOTTLE (23155-621-02) CALCIUM ACETATE Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2015-01-22
62135-0192-22 200 TABLET in 1 BOTTLE (62135-192-22) Calcium Acetate Chartwell RX LLC 2019-07-01
Observed labelers: Chartwell RX LLC (1) · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.4489
Range $0.4489–$0.4489 · middle 50% $0.4489–$0.4489 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.